Back to Journals » Biologics: Targets and Therapy » Volume 14

Fetal Acrania (Exencephaly) in the Context of a Pregnant Female Taking Adalimumab for Psoriasis: A Case Report

Authors Daham N, AlMuqrin A, Madani A, AlSaif F

Received 24 July 2020

Accepted for publication 16 October 2020

Published 11 November 2020 Volume 2020:14 Pages 127—129


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Doris Benbrook

Nujud Daham,1 Abdullah AlMuqrin,2 Abdulaziz Madani,3 Fahad AlSaif3

1Department of Dermatology, Dr. Sulaiman Al-Habib Medical Group, Riyadh, Saudi Arabia; 2Department of Dermatology, Prince Mohammed Bin Abdulaziz Medical City, Riyadh, Saudi Arabia; 3Department of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia

Correspondence: Nujud Daham
Department of Dermatology, Dr. Sulaiman Al-Habib Medical Group, King Fahad Road, Olaya, Po Box 91877, Riyadh 11643, Saudi Arabia
Tel +966 500211134

Abstract: Adalimumab is a fully human, recombinant, IgG1 monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha). It has been established that adalimumab can cross the placenta and can be detected in the fetal circulation for up to 6 months postpartum. However, clinical studies have failed to show any consistent or specific adverse fetal outcomes from maternal exposure to adalimumab during pregnancy. In our report, we present a case of fetal acrania (exencephaly) in the setting of a pregnant female taking adalimumab prior to and during pregnancy. Exencephaly is a neural tube defect (NTD) that results from failure of closure of the neural fold. It is true that there were other risk factors that might have contributed to our patient’s unfortunate outcome. For example, she did not take folic acid supplementation prior to or during her pregnancy. Nonetheless, studies have shown that folic acid deficiency alone is not sufficient to lead to the development of NTDs. Our patient’s exposure to adalimumab during her pregnancy might have added to the risk in her situation. Our report aims to inform clinicians of that possible risk and to stimulate them to report any similar outcomes.

Keywords: adalimumab, exencephaly, neural tube defects, pregnancy, psoriasis, TNF-α

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]